Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
44
BCLI Quote, Financials, Valuation and Earnings
Last price:
$0.60
Seasonality move
:
24.38%
Day range:
$0.56 - $0.60
52-week range:
$0.52 - $2.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
46.1K
Avg. volume:
20.4K
1-year change:
-73.54%
Market cap:
$6.6M
Revenue:
--
EPS (TTM):
-$1.46
Analysts' Opinion
-
Consensus RatingBrainstorm Cell Therapeutics, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $17.00, Brainstorm Cell Therapeutics, Inc. has an estimated upside of 2713.17% from its current price of $0.59.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $17.00 representing 100% downside risk from its current price of $0.59.
Fair Value
-
According to the consensus of 1 analyst, Brainstorm Cell Therapeutics, Inc. has 2713.17% upside to fair value with a price target of $17.00 per share.
BCLI vs. S&P 500
-
Over the past 5 trading days, Brainstorm Cell Therapeutics, Inc. has overperformed the S&P 500 by 2.72% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Brainstorm Cell Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Brainstorm Cell Therapeutics, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Brainstorm Cell Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
Brainstorm Cell Therapeutics, Inc. has grown year-over-year earnings for 4 quarters straight. In the most recent quarter Brainstorm Cell Therapeutics, Inc. reported earnings per share of -$0.19.
Enterprise value:
7.1M
EV / Invested capital:
-0.98x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.17x
EV / Free cash flow:
-0.97x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$204K
Return On Assets:
-476.79%
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$269K | -$253K | -$204K | -$59K | -$48K | |
| Operating Income | -$21.6M | -$13.3M | -$10.9M | -$3M | -$2M | |
| EBITDA | -$21.3M | -$13.1M | -$10.7M | -$3M | -$2M | |
| Diluted EPS | -$6.55 | -$3.49 | -$1.46 | -$0.51 | -$0.19 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $27.9M | $7.5M | $1.5M | $364K | $508K | |
| Total Assets | $34.5M | $13.3M | $5.7M | $2M | $1.4M | |
| Current Liabilities | $5.8M | $8.9M | $6.3M | $7.1M | $9M | |
| Total Liabilities | $9.6M | $11.9M | $8.3M | $8.1M | $9.1M | |
| Total Equity | $24.9M | $1.4M | -$2.6M | -$6.1M | -$7.7M | |
| Total Debt | $3.8M | $2.9M | $1.6M | $271K | $50K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$21.8M | -$11.3M | -$7.3M | -$3.3M | -$1.1M | |
| Cash From Investing | $3M | $196K | $12K | -- | -- | |
| Cash From Financing | $15.9M | $10.3M | $7.2M | -- | $313K | |
| Free Cash Flow | -$21.8M | -$11.3M | -$7.3M | -$3.3M | -$1.1M | |
BCLI
Sector
Market Cap
$6.6M
$28M
Price % of 52-Week High
24%
51.03%
Dividend Yield
0%
0%
Shareholder Yield
-87.1%
-1.54%
1-Year Price Total Return
-70.81%
-17.48%
Beta (5-Year)
-0.928
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$0.57
200-day SMA
Sell
Level
$0.90
Bollinger Bands (100)
Sell
Level
0.61 - 0.71
Chaikin Money Flow
Sell
Level
-129M
20-day SMA
Sell
Level
$0.59
Relative Strength Index (RSI14)
Sell
Level
47.99
ADX Line
Buy
Level
28.47
Williams %R
Neutral
Level
-33.3766
50-day SMA
Sell
Level
$0.63
MACD (12, 26)
Sell
Level
-0.02
25-day Aroon Oscillator
Sell
Level
-72
On Balance Volume
Neutral
Level
183.4M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-199.013)
Sell
CA Score
(Annual)
Level (-29.8105)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (51.8123)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (1)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Brainstorm Cell Therapeutics, Inc. is a biotechnology company, which develops and commercializes autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis, Progressive Multiple Sclerosis, Alzheimer's disease, and other neurodegenerative diseases. Its pipeline, NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and improve neurological function. The company was founded by Irit Arbel on September 22, 2000 and is headquartered in New York, NY.
Stock Forecast FAQ
In the current month, BCLI has received 0 Buy ratings 1 Hold ratings, and 0 Sell ratings. The BCLI average analyst price target in the past 3 months is $17.00.
-
Where Will Brainstorm Cell Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Brainstorm Cell Therapeutics, Inc. share price will rise to $17.00 per share over the next 12 months.
-
What Do Analysts Say About Brainstorm Cell Therapeutics, Inc.?
Analysts are divided on their view about Brainstorm Cell Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Brainstorm Cell Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $17.00.
-
What Is Brainstorm Cell Therapeutics, Inc.'s Price Target?
The price target for Brainstorm Cell Therapeutics, Inc. over the next 1-year time period is forecast to be $17.00 according to 1 Wall Street analyst, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is BCLI A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Brainstorm Cell Therapeutics, Inc. is a Hold. 1 of 1 analysts rates the stock a Hold at this time.
-
How Can I Buy Shares Of BCLI?
You can purchase shares of Brainstorm Cell Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Brainstorm Cell Therapeutics, Inc. shares.
-
What Is The Brainstorm Cell Therapeutics, Inc. Share Price Today?
Brainstorm Cell Therapeutics, Inc. was last trading at $0.60 per share. This represents the most recent stock quote for Brainstorm Cell Therapeutics, Inc.. Yesterday, Brainstorm Cell Therapeutics, Inc. closed at $0.59 per share.
-
How To Buy Brainstorm Cell Therapeutics, Inc. Stock Online?
In order to purchase Brainstorm Cell Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get BCLI Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
BCLI
Sector
P/E ratio
--
23.89x
PEG ratio
-0.17x
-0.01x
P/B ratio
--
1.82x
Price / LTM sales
--
1.60x
Growth Metrics
BCLI
Sector
Revenue growth
--
4.62%
Earnings growth
62.49%
10.88%
Revenue (5-year growth)
--
6.5%
Earnings forecast
-$0.39
-$0.21
Profitability
BCLI
Sector
Profitability FY 2024
-$240K
$3.5M
Return on invested capital
--
-31.77%
Return on assets
-476.79%
-27.96%
Return on equity
--
-37.63%
Earnings Date
Last Earnings Date
Nov
14
Next Earnings Date
Mar
31
Estimated Next Earnings Date
Feb
13
Balance Sheet
BCLI
Sector
Total cash
$5K
$26.3M
Short term investments
--
$25.7M
Total assets
$1.8M
$78M
Long term debt
$50K
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
